| 研究課題/領域番号 |
24406031
|
|---|
| 応募区分 | 海外学術 |
|---|
| 研究機関 | 長崎大学 |
|---|
研究代表者 |
ログノビッチ タチアナ 長崎大学, 原爆後障害医療研究所, 助教 (30423643)
|
|---|
| 研究分担者 |
SAENKO Vladimir 長崎大学, 原爆後障害医療研究所, 准教授 (30343346)
中島 正洋 長崎大学, 原爆後障害医療研究所, 教授 (50284683)
柴田 義貞 長崎大学, 医歯(薬)学総合研究科, 客員教授 (40010954)
|
|---|
| 研究期間 (年度) |
2012-04-01 – 2015-03-31
|
| キーワード | 小児甲状腺乳頭癌 / パラフィン組織バンク / 次世代シーケンシング / 新規癌遺伝子 |
|---|
| 研究概要 |
During 25年 we accomplished collection of paraffin-embedded tissues and nearly finished to collect blood samples from the most aggressive (young age of exposure and short-latent period) pediatric PTCs (operated from 1990 and until October 1998), which are not included in the Chernobyl Tissue Bank by dispatching two specialists to affected after Chernobyl fallout areas of Belarus and Ukraine. For all collected PTC samples we made data base of patients, which includes demographic, clinical and morphological information.
From all collected blood samples we extracted DNA and from all Normal and Tumor counterparts of paraffin-embedded PTC samples we extracted DNA and RNA from some of them. We performed genetic analysis of all extracted Normal and Tumor PTC samples for known mutations (BRAF, H-, K-, N-RAS) and rearrangements (RET/PTC1, RET/PTC3 and AKAP9/BRAF).
For five pairs of PTC samples (Normal and Tumor) we performed DNA mutational analysis (all exons) using next-generation sequencing HiSeq system (Illumina). Within these five PTC samples, two had RET/PTC rearrangements (RET/PTC3 and RET/PTC1), but three others do not harbor any other known mutations and rearrangements.
For two additional Tumor PTC samples we performed mRNA whole genome fusion gene and mutational analysis using next-generation sequencing HiSeq system (Illumina). We chose two PTC samples without any known mutations and rearrangement, with solid and solid-trabecullar histological structures and with the same stage (T1N1bMO).
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
ほぼ、当初の計画道り進行している。
|
| 今後の研究の推進方策 |
During 26年 we plan to accomplish collection of blood samples by dispatching specialists to affected after Chernobyl fallout areas, further development of database and performing DNA extraction from all collected blood samples.
We plan to perform biostatistical analysis of obtained data of DNA-exome sequence (point mutations) and mRNA whole genome sequence data (expressed rearrangements and point mutations) to narrow the spectrum of putative new cancer “driver” rearrangement and/or point mutation followed by verification of detected mutation/rearrangements by capillary sequencing, and frequency determination in all DNA samples extracted from paraffin-embedded tissues, and functional study.
|
| 次年度の研究費の使用計画 |
Originally we were going to analyze more PTC cases using a next-generation sequencing HiSeq system (Illumina), however we decided to enroll a smaller number of PTCs.
We plan to use the remaining money for functional analysis to find new “driver” oncogenes.
|
